证券之星消息，11月7日AI 医疗板块较上一交易日下跌0.83%，麦迪科技领跌。当日上证指数报收于 3997.56，下跌0.25%。深证成指报收于13404.06，下跌0.36%。AI 医疗板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300451 | 创业慧康 | 5.18 | 7.02% | 132.79万 | 6.74亿 | | 688246 | 嘉和美康 | 25.11 | 0.88% | 3.26万 | 8137.05万 | | 002030 | 达安基因 | 6.59 | 0.76% | 14.14万 | 9293.80万 | | 301602 | 超研股份 | 24.88 | 0.32% | 1.95万 | 4850.64万 | | 002524 | 光正眼科 | 4.67 | 0.21% | 8.47万 | 3939.21万 | | 300078 | 思创医惠 | 3.57 | 0.00% | 25.12万 | 8923.51万 | | 300244 | ...

会议召开时间：2025年11月12日(星期三) 下午 13:15-14:45 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603990 证券简称：麦迪科技 公告编号：2025-073 苏州麦迪斯顿医疗科技股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议参与方式一：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/）； 会议参与方式二："麦迪科技投资者关系"小程序，通过微信搜索"麦迪科技投资者关系"或微信扫一扫以 下二维码参与会议 ■ 会议召开方式：视频直播和网络互动 投资者可于2025年11月05日(星期三)至11月11日(星期二)16:00前登录上证路演中心网站首页点击"提问预 征集"栏目或通过公司邮箱suzhoumedi001@medicalsystem.cn进行提问。公司将在说明会上对投资者普遍 关注的问题进行回答。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）已于202 ...

一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2025 年第三季度的经营成果及财务指标的具体情况与投资者进行互动交 流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回 答。 投资者可于 2025 年 11 月 05 日(星期三)至 11 月 11 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 suzhoumedi001@medicalsystem.cn 进行提问。公司将 在说明会上对投资者普遍关注的问题进行回答。 证券代码：603990 证券简称：麦迪科技 公告编号：2025-073 苏州麦迪斯顿医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开方式：视频直播和网络互动 会议召开时间：2025 年 11 月 12 日(星期三) 下午 13:15-14:45 会议参与方式一：上海证券交易所上证路演中心（网址： http://roadshow.ssei ...

Core Insights - The company reported significant improvement in its financial performance for the first three quarters of 2025, achieving a revenue of 223 million yuan and a net profit of 34.27 million yuan, marking a substantial turnaround from losses in the same period last year [1] - The company has successfully completed the divestiture of its photovoltaic business and refocused on its core medical operations, demonstrating the effectiveness of its strategic pivot [1] - The company has made notable advancements in the field of domestic software adaptation and innovation, ensuring compatibility with major domestic hardware and software platforms, which aligns with national technology requirements [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 223 million yuan and a net profit of 34.27 million yuan, indicating a significant recovery compared to the previous year's losses [1] Strategic Developments - The company has completed the localization and adaptation of critical software for severe illness management, ensuring deep compatibility with mainstream domestic hardware and software platforms [1] - The company participated in the launch of the Global Education Healthcare Partners Alliance (GEHPA) initiated by Huawei, which includes industry leaders from over 40 countries, aimed at driving innovation and shared opportunities in the education and healthcare sectors [2] Technological Advancements - The company has established a comprehensive ecosystem in the smart healthcare sector, collaborating with partners like Huawei to develop a task-driven intelligent platform for elderly care, integrating computing power, large models, robotics, and data collection [2] - The company is positioned as a supplier of comprehensive smart healthcare solutions and a developer of real application scenarios, leveraging over 20 years of experience in medical information technology [2] Future Outlook - The management has expressed a commitment to deepen its focus on the medical sector, aiming to enhance its competitive advantage through ongoing technological research and product optimization for sustainable development [3]

证券代码：603990 证券简称：麦迪科技 公告编号：2025-072 苏州麦迪斯顿医疗科技股份有限公司 第四届监事会第十九次会议决议公告 特此公告。 苏州麦迪斯顿医疗科技股份有限公司监事会 二、监事会会议审议情况 （一）审议了《关于公司 2025 年第三季度报告的议案》； 监事会认为：公司 2025 年第三季度报告的编制和审议程序符合法律、法规、 公司章程和公司内部管理制度的各项规定；第三季度报告的内容和格式符合中国 证监会和上海证券交易所的各项规定，所包含的信息能从各个方面真实地反映出 公司 2025 年第三季度的经营状况、成果和财务状况。 同意《苏州麦迪斯顿医疗科技股份有限公司 2025 年第三季度报告》。 具体内容详见公司同日披露的《苏州麦迪斯顿医疗科技股份有限公司 2025 年第三季度报告》 表决结果：同意 3 票；反对 0 票；弃权 0 票。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）第四届监事会第 十九次会议于 2025 年 10 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603990 证券简称：麦迪科技 公告编号：2025-071 苏州麦迪斯顿医疗科技股份有限公司 第四届董事会第三十六次会议决议公告 特此公告。 苏州麦迪斯顿医疗科技股份有限公司董事会 2025 年 10 月 30 日 一、董事会会议召开情况 具体内容详见公司同日披露的《苏州麦迪斯顿医疗科技股份有限公司 2025 年第三季度报告》。 表决结果：同意 5 票；反对 0 票；弃权 0 票。 公司审计委员会审议并通过了本议案。审计委员会认为：公司 2025 年第三 季度报告真实、准确、完整地反映了公司经营管理和财务等各方面的实际情况， 不存在任何虚假记载、误导性陈述或者重大遗漏。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）第四届董事会第 三十六次会议于 2025 年 10 月 28 日以通讯表决的方式召开。本次董事会会议通 知于 2025 年 10 月 24 日以邮件形式发出。会议由董事长陈宁先生召集并主持， 会议应出席董事 5 名，实际出席董事 5 名，公司监事会成 ...

Revenue and Profitability - Revenue for Q3 2025 was CNY 87,708,575.06, a decrease of 15.68% compared to the same period last year[3] - Year-to-date revenue reached CNY 222,912,349.82, down 38.13% year-over-year[3] - Net profit attributable to shareholders for Q3 2025 was CNY 5,942,355.49, with a year-to-date net profit of CNY 34,269,812.83[3] - Basic earnings per share for Q3 2025 was CNY 0.02, unchanged from the previous period[4] - The company reported a net loss of CNY 204,554,988.59 for the first three quarters of 2025, an improvement from a net loss of CNY 238,824,801.42 in the same period of 2024[13] - The net profit for the first three quarters of 2025 is CNY 36,097,511.29, a significant recovery from a net loss of CNY -166,251,751.36 in the same period of 2024[15] - Operating profit for the current period is CNY 38,512,946.55, compared to a loss of CNY -159,160,870.71 in the previous year[15] - The total comprehensive income for the current period is CNY 36,097,511.29, compared to a total comprehensive loss of CNY -166,251,751.36 in the same period last year[16] Cash Flow and Liquidity - The company reported a significant improvement in cash flow from operating activities, with a net cash flow of CNY 12,812,043.23 year-to-date[3] - Cash flow from operating activities shows a net inflow of CNY 12,812,043.23, improving from a net outflow of CNY -45,585,403.83 in the prior year[17] - Cash flow from investing activities has a net inflow of CNY 225,523,580.03, recovering from a net outflow of CNY -72,306,847.78 in the same period last year[18] - Total cash and cash equivalents at the end of the period stand at CNY 239,632,571.26, up from CNY 144,121,483.02 at the end of the previous year[18] - Cash and cash equivalents increased to CNY 252,445,201.14 as of September 30, 2025, compared to CNY 119,336,851.27 at the end of 2024, representing a growth of 111.4%[11] - The company has reported a decrease in cash received from tax refunds to CNY 7,866,080.63 from CNY 151,795,357.26 in the previous year[17] Assets and Liabilities - Total assets decreased by 60.55% to CNY 1,248,366,147.81 compared to the end of the previous year[4] - Total assets decreased to CNY 1,248,366,147.81 as of September 30, 2025, down from CNY 3,164,052,059.39 at the end of 2024[12] - Total liabilities decreased to CNY 404,569,775.22 as of September 30, 2025, compared to CNY 2,359,264,396.45 at the end of 2024[12] - The company’s total equity increased to CNY 843,796,372.59 as of September 30, 2025, compared to CNY 804,787,662.94 at the end of 2024[13] Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.27% to CNY 833,813,770.16[4] - The total number of ordinary shareholders at the end of the reporting period was 38,943[9] Operational Performance - The disposal of the photovoltaic business in January 2025 led to a reduction in operational losses and a return to profitability in the medical sector[7] - Total operating revenue for the first three quarters of 2025 was CNY 222,912,349.82, a decrease of 38.1% compared to CNY 360,301,548.27 in the same period of 2024[14] - Total operating costs for the first three quarters of 2025 were CNY 211,917,664.40, down 63.4% from CNY 579,593,276.48 in the previous year[14] - Research and development expenses for the first three quarters of 2025 amounted to CNY 21,794,272.31, a reduction of 49.7% compared to CNY 43,316,194.03 in 2024[14] Investment Performance - The company’s long-term equity investments were valued at CNY 15,039,043.87 as of September 30, 2025, down from CNY 15,942,052.41 at the end of 2024[11] - The company has received CNY 390,000,000.00 from the recovery of investments, compared to CNY 469,000,000.00 in the same period last year[18]

Group 1 - The DRG/DIP concept declined by 1.31%, ranking among the top declines in the concept sector, with notable declines in companies like Jiarun Technology, Jiahe Meikang, and ST Yilianzhong [1][2] - Among the DRG/DIP concept stocks, six companies saw price increases, with Madi Technology, Weining Health, and Shanda Diwei leading the gains at 2.98%, 1.29%, and 1.29% respectively [1][2] - The DRG/DIP concept experienced a net outflow of 379 million yuan, with 18 stocks facing net outflows, and Jiarun Technology leading with a net outflow of 135 million yuan [2][3] Group 2 - The top gainers in today's concept sectors included Hainan Free Trade Zone at 4.35%, BC Battery at 3.89%, and Metal Zinc at 3.60%, while several sectors like DRG/DIP and others faced declines [2] - The main stocks with significant net inflows included Madi Technology, Huaping Co., and Shanda Diwei, with net inflows of 19.93 million yuan, 13.24 million yuan, and 8.86 million yuan respectively [2][3] - The stocks with the highest net outflows in the DRG/DIP concept included Jiarun Technology, Dongruan Group, and Donghua Software, with net outflows of 135.44 million yuan, 61.65 million yuan, and 57.21 million yuan respectively [2][3]

Core Insights - The internet healthcare sector experienced a slight increase of 0.21% on October 29, with notable gains from companies like Jiangyu Pingmin, which rose by 6.29% [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Company Performance - Jiangyu Pingmin (301017) closed at 11.99 with a gain of 6.29%, trading volume of 201,100 shares and a transaction value of 242 million [1] - Furuishi (300049) closed at 74.48, up 6.20%, with a trading volume of 150,500 shares and a transaction value of 1.104 billion [1] - Xingqi Eye Medicine (300573) closed at 82.01, increasing by 5.29%, with a trading volume of 309,400 shares and a transaction value of 2.518 billion [1] - Other notable performers include Maidi Technology (603990) with a 2.98% increase and a transaction value of 384 million, and Hanhui Technology (300007) with a 2.68% increase and a transaction value of 1.402 billion [1] Market Dynamics - The internet healthcare sector saw a net outflow of 1.125 billion from institutional investors, while retail investors contributed a net inflow of 926 million [2][3] - The overall market sentiment indicated a mixed response, with some stocks experiencing significant declines, such as Jiayuan Technology (301117) which fell by 13.29% [2] - The trading activity highlighted a divergence in investor behavior, with institutional investors pulling back while retail investors remained active [2][3]

证券代码：603990 证券简称：麦迪科技 公告编号：2025-070 苏州麦迪斯顿医疗科技股份有限公司 关于使用部分闲置募集资金进行现金管理赎回的公告 二、 闲置募集资金现金管理总体情况 公司使用闲置募集资金购买的产品不存在逾期未收回的情况。截至本公告披 露日，公司使用募集资金购买产品的余额为7,000.00万元。 特此公告。 苏州麦迪斯顿医疗科技股份有限公司董事会 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第四届董事会第三十一次会议、第四届监事会第十五次会议，审议通 过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影 响募集资金投资项目进度和募集资金安全的前提下，对暂时闲置的部分募集资金 不超过人民币 2 亿元（包含本数）进行现金管理，余额在上述额度内，资金可以 滚动使用，用于购买单笔期限最长不超过 12 个月（含 12 个月）的结构性存款等 安全性高的保本型产品，不得用于证券投资。公司董事会、监事会及保荐机构已 分别对前述事项发表了同意的意见。具体内容详见公司于 2025 年 4 月 30 日披露 的《关于使用部分闲置募集资金进行现金管 ...